A Global Study of the PETAL Consortium
NCT06067347
This study is recruiting at 10 US sites in 9 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize that machine learning can be leveraged to uncover distinct genetic vulnerabilities that underlie treatment response and resistance for patients with TNKL, thus moving towards personalized treatment solutions.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- T-Cell and NK-Cell Neoplasm
Eligibility basics and study details
- Study type
- Observational
- Phase
- Not applicable
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Accepted
- Sponsor
- Massachusetts General Hospital
- Last updated on ClinicalTrials.gov
- April 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
California · 1
- City of Hope · Duarte, CA
Colorado · 1
- University of Colorado · Denver, CO
Florida · 1
- Moffitt Cancer Center · Tampa, FL
Massachusetts · 2
- Dana-Farber Cancer Institute · Boston, MA
- Massachusetts General Hospital · Boston, MA
Minnesota · 1
- Mayo Clinic · Rochester, MN
New Jersey · 1
- Hackensack University Medical Center · Hackensack, NJ
Ohio · 1
- OhioHealth · Columbus, OH
Pennsylvania · 1
- University of Pennsylvania · Philadelphia, PA
Virginia · 1
- University of Virginia · Charlottesville, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.